Human Amniotic Epithelial Stem Cells is under clinical development by ICELL Biotechnology and currently in Phase I for Graft Versus Host Disease (GVHD). According to GlobalData, Phase I drugs for Graft Versus Host Disease (GVHD) have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Human Amniotic Epithelial Stem Cells’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Human Amniotic Epithelial Stem Cells overview
Stem cell therapy is under development for the treatment of idiopathic Parkinson's disease, Asherman syndrome, primary ovarian insufficiency (premature ovarian failure), graft versus host disease, acute renal failure (ARF) (acute kidney injury) and chronic kidney damage, uveitis, hashimoto thyroiditis, systemic lupus erythematosus and for spinal cord injury and unspecified indication. It is administered by intrathecal and parenteral routes as an infusion. The drug candidate is a colorless translucent suspension of human amniotic epithelial cells (hAECs). It was also under development for the treatment of bronchial fistula, spastic cerebral palsy.
For a complete picture of Human Amniotic Epithelial Stem Cells’s drug-specific PTSR and LoA scores, buy the report here.